

Table 5

In this guide

[In this guide](#)

1. [Table 3 - Annex A](#)
2. [Table 4 - Annex A](#)
3. [Table 5 - Annex A](#)
4. [Table 6 - Annex A](#)
5. [Table 7 - Annex A](#)
6. [Table 8 - Annex A](#)
7. [Table 9 - Annex A](#)
8. [Table 10 - Annex A](#)
9. [Table 11 - Annex A](#)
10. [Table 12 - Annex A](#)
11. [Table 13 - Annex A](#)
12. [Table 14 - Annex A](#)
13. [Table 15 - Annex A](#)
14. [Table 16 - Annex A](#)
15. [Table 17 - Annex A](#)
16. [Table 18 - Annex A](#)
17. [Table 19 - Annex A](#)
18. [Table 20 - Annex A](#)
19. [Table 21 - Annex A](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Table 5. Acute toxicity studies for PFCAs - PFDA

*Derived by contractor; ** calculated according to EFSA. (2012); NR – not reported; NA – not applicable.

Substance / CAS no. / purity / reference	Strain & species / sex / no. of animals	Dose (mg/kg bw/day) / vehicle / route of admin / duration / Guideline (GL) study / Good Laboratory Practice (GLP) status	PFAS concentration (µg/mL / µg/g)	Observed effects at LOAEL (controls vs treated groups). Recovery (controls vs treated groups).	P N L (b
---	--	--	---	--	-----------------------

PFDA

0, 5, 15 or 25

Males:

CAS No. not given F-344 rats

Propyleneglycol:water
i.p.

↑ fatty acyl-Co A oxidase
activity (data only
reported in figures).

Purity not given. Male
4-5.

NR

Recovery not assessed.

Adinehzadeh
et al. (1999)

Single dose,
Non-GL study,
GLP not stated.

Males (mean \pm SE):

\uparrow total lipids (mg/g liver):
 54.6 ± 4.2 vs 37.1 ± 1.7 ,

\uparrow phosphatidylcholine
($\mu\text{mol/g liver}$): 34.0 ± 3.4
vs 26.5 ± 1.4),

\uparrow
phosphatidylethanolamine:
 12.6 ± 1.3 vs 9.6 ± 0.4 .

Recovery not assessed.

PFDA		0, 15 or 50	
CAS No. not given	F-344 rats	Propyleneglycol:water i.p.	
Purity not given.	Male	Single dose,	NR
	5-6.	Non-GL study,	
Adinehzadeh et al. (1999)		GLP not stated.	

PFDA		0, 0.5, 1.0, 10, 20, 40 or 80,
CAS No. not given	C57BL/6 mice	Propyleneglycol:water i.p.
96%.	Male	Single dose,
Cheng and Klaassen (2008)	4/dose.	Non-GL study, GLP not stated.

NR

Males:

↑ mRNA of cyp4A14 (data
only reported in figures).

Recovery not assessed.

PFDA

0 or 80

Males:

CAS No. not
given

C57BL/6
mice

Propyleneglycol:water
i.p.

↑ mRNA of Cyp2B10,

3A11 and 4A14

96%.

Male

Single dose,

NR

↑ protein levels of Cyp2B
and 4A (data only reported
in figures).

Cheng and
Klaassen
(2008)

5/dose.

Non-GL study,

GLP not stated.

Recovery not assessed.

PFDA				Males:
CAS No. not given	Wistar rats	0, 0.00125, 0.0025, 0.005 or 0.01% equivalent to 0, 1.5, 3, 6 or 12**, i.p.	NR	↑ relative liver weight (data only reported in figures)
Purity not given.	Male			↑ acyltransferase activity (data only reported in figures)
Kawashima et al. (1995)	4/dose.	5 days.		↑ TG (data only reported in figures).
				Recovery not assessed.